Company Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 19/04/2024 BST 5-day change 1st Jan Change
66.76 USD +0.91% Intraday chart for Gilead Sciences, Inc. -1.92% -17.59%

Business Summary

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Number of employees: 18,000

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Medicines
100.0 %
27,281 100.0 % 27,116 100.0 % -0.60%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
71.7 %
18,884 69.2 % 19,438 71.7 % +2.93%
Europe
15.9 %
4,469 16.4 % 4,310 15.9 % -3.56%
Other International
12.4 %
3,928 14.4 % 3,368 12.4 % -14.26%

Managers

Managers TitleAgeSince
Chief Executive Officer 58 28/02/19
Director of Finance/CFO 54 31/12/15
Chief Tech/Sci/R&D Officer - 11/04/21
Chief Tech/Sci/R&D Officer 61 31/10/19
Investor Relations Contact - 31/12/20
Corporate Officer/Principal - -
Corporate Officer/Principal 54 17/07/22
Corporate Officer/Principal - -
Human Resources Officer 48 31/10/17
Corporate Officer/Principal - 31/12/18

Members of the board

Members of the board TitleAgeSince
Director/Board Member 69 16/10/20
Director/Board Member 71 31/12/17
Director/Board Member 65 01-31
Director/Board Member 69 28/07/09
Director/Board Member 70 08/05/18
Director/Board Member 53 14/06/20
Chief Executive Officer 58 28/02/19
Director/Board Member 75 27/01/20
Director/Board Member 56 18/08/16
Director/Board Member 70 06/12/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,246,969,303 1,245,771,596 ( 99.90 %) 0 99.90 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
8.976 %
111,822,428 8.976 % 8 191 M $
BlackRock Advisors LLC
7.472 %
93,089,266 7.472 % 6 819 M $
Capital Research & Management Co. (World Investors)
6.692 %
83,364,123 6.692 % 6 106 M $
Capital Research & Management Co. (Global Investors)
4.789 %
59,657,126 4.789 % 4 370 M $
59,536,425 4.779 % 4 361 M $
Dodge & Cox
2.673 %
33,295,023 2.673 % 2 439 M $
ishares (DE) Invag Mit Teilgesellschaftsvermogen
2.205 %
27,471,926 2.205 % 2 012 M $
Geode Capital Management LLC
2.029 %
25,274,185 2.029 % 1 851 M $
Wellington Management Co. LLP
1.495 %
18,630,134 1.495 % 1 365 M $
Eaton Vance Management
1.429 %
17,801,718 1.429 % 1 304 M $
NameEquities%Valuation
BB Gestão de Recursos DTVM SA
0.000361 %
8,986 0.000361 % 325 274 $
Bram Bradesco Asset Management S/A DTVM
0.000221 %
5,500 0.000221 % 199 088 $
Western Asset Management Company DTVM Ltda.
0.000002 %
59 0.000002 % 2 136 $

Holdings

NameEquities%Valuation
31,532,781 34.70% 595,338,905 $
16,707,477 25.35% 533,743,743 $
6,720,803 12.73% 467,431,849 $
4,126,119 9.57% 102,492,796 $
4,854,443 4.55% 38,544,277 $
1,089,468 19.87% 14,489,924 $
18,759,465 23.00% 13,356,739 $
16,635,286 14.58% 12,559,641 $
7,345,473 26.67% 7,933,111 $
2,931,467 6.07% 4,162,683 $

Company contact information

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+650 574 3000

http://www.gilead.com
address Gilead Sciences, Inc.(GILD)

Group companies

NameCategory and Sector
Gilead Sciences Ireland UC
Pharmaceuticals: Major

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
66.76 USD
Average target price
85.25 USD
Spread / Average Target
+27.69%
Consensus
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Company Gilead Sciences, Inc.